At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-Label Randomized Phase II Trial of Megestrol Acetate With or Without Pterostilbene in Patients With Endometrial Cancer Scheduled for Hysterectomy
In Brief
A Phase 2 clinical trial evaluating Megestrol Acetate and Pterostilbene for Atypical Endometrial Hyperplasia and Endometrial Carcinoma. Active but no longer recruiting, targeting 44 participants across 1 site.
Signals
Detailed Summary
This phase II trial studies how well megestrol acetate with or without pterostilbene works in treating patients with endometrial cancer undergoing hysterectomy. Drugs used in chemotherapy, such as megestrol acetate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pterostilbene is an antioxidant found in blueberries or grapes, and it has been shown to be effective in killing tumor cells and reducing cancer burden. It is not yet known whether giving megestrol acetate with or without pterostilbene may work better in treating patients with endometrial cancer.
Study Details
Timeline
Arms & Interventions
Patients receive 100mg pterostilbene BID and 80mg megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
Patients receive megestrol acetate PO BID for 3 weeks in the absence of disease progression or unaccepted toxicity.
Interventions
Given PO
Given PO